The London School of Economics and Political Science (LSE) and Boston Consulting Group (BCG), in collaboration with some of the world’s leading pharmaceutical companies, have come together to create The LSE Health Market Access Academy.
The LSE Health Market Access Academy aims to train top performers from all of the world’s leading pharmaceutical companies, giving them advanced knowledge and strategies in the field of market access.
AbbVie, AstraZeneca, Amgen, Bayer, Eli Lilly, Janssen, Merck EMD, Pfizer, Roche, Sanofi, Takeda and UCB have joined this initiative to create what will be the first collaborative market access management development program.
This executive program is aimed at present and future Market Access Leaders within pharmaceutical companies. Based on key business needs, it will provide participants with a common grounding in market access, training in representative decision-making across the product life-cycle and strategies to adapt to a rapidly changing industry landscape.
A program of lectures, case studies, workshop discussions and VIP guest speakers will give technical experts as well as those from other functions the tools to understand the market access environment, plan strategy, and optimise access and value.
The weeklong program will consist of five modules that will deepen participants’ market access knowledge. The Market Access Academy will begin with understanding access drivers and barriers, define an integrated evidence package, create a receptive access environment, optimise access and value, and manage access strategy.
The first two waves of the LSE Health Market Access Academy will take place from 27-31 March and 11-15 September 2017 in London, with future international delivery dates to be announced in 2018. Participants are expected from the EU, US, Japan, the BRICS countries and emerging markets.